Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
Multiple myeloma is a plasma cell malignancy primarily affecting middle-aged and elderly individuals. Patients often seek medical attention due to bone pain and fatigue. Originating from abnormal plasma cell clonal proliferation in the bone marrow, it can cause osteolytic lesions in multiple bone marrow sites. Treatment requires comprehensive intervention focusing on both survival and functionality.
Multiple myeloma is relatively common in Europe and the U.S., with incidence steadily rising. In parts of Asia, such as Japan, South Korea, and Singapore, cases have also increased in recent years. Southeast Asian countries such as Thailand and Malaysia are seeing gradual growth as well. With population aging, global attention is increasing.
The U.S. reports approximately 36,000 new MM cases annually, with 13,000 deaths, corresponding to an annual incidence rate of about 7 per 100,000. The rates in Canada, the South Thames region of the U.K., and Europe overall are similar. Globally, there are approximately 180,000 new MM cases and 117,000 deaths each year.
1. Skeletal complications
Osteolytic lesions lead to severe pain in the spine, sternum, and other sites, and may cause pathological fractures, restricting activity and quality of life.
2. Immune dysfunction
Clonal plasma cells occupy the bone marrow and suppress normal immune cells, predisposing patients to recurrent infections such as pneumonia and urinary tract infections.
3. Anemia and fatigue
Abnormal cells crowd out normal bone marrow, reducing red blood cell production and causing common symptoms such as fatigue and pallor.
4. Kidney damage
Excess immunoglobulins may deposit in renal tubules, leading to impaired kidney function and even renal failure.
Immune reconstruction cell therapy induces autologous or engineered immune cells to reshape anti-tumor immune responses. It is suitable for patients with relapsed, drug-resistant, or multi-line treated disease who lack other therapeutic options.
① Improve immune surveillance;
② Delay disease progression;
③ Combined with stem cell transplantation, efficacy can be enhanced;
④ Lower side effects and broader adaptability.
In clinical practice, cancer patients undergoing traditional treatments such as surgery, radiotherapy, and chemotherapy often face immune dysfunction, increased infection risk, and slow recovery. To help patients better sustain treatment, improve tolerance, and enhance quality of life, it is necessary to scientifically develop phased immune reconstruction plans tailored to different treatment cycles.
● Short-term plan: Rapidly enhance immunity through immune cell reinfusion to boost the effectiveness of anti-tumor therapy.
● Mid-term plan: Reduce side effects of traditional treatments, promote physical recovery, and complete standardized treatment courses.
● Long-term plan: Strengthen overall immunity through immune cell reconstruction, gut immune reconstruction, elemental immune reconstruction, and immune nutrition reconstruction, thereby improving quality of life and prolonging survival.
1. Autologous stem cell transplantation
Autologous stem cell transplantation combined with high-dose chemotherapy is an important treatment option for younger or physically fit patients. It clears clonal cells while restoring normal hematopoietic function.
2. Targeted drugs and proteasome inhibitors
Drugs such as bortezomib and lenalidomide target tumor cell growth mechanisms and control abnormal protein metabolism. These agents, available in oral or injectable forms, are commonly used for initial and maintenance therapy.
3. Chemotherapy and corticosteroids
Traditional chemotherapeutic agents such as cyclophosphamide combined with steroids can provide rapid symptom relief, commonly used in acute-phase treatment protocols to manage symptoms effectively.
4. Minimally invasive interventions and local treatments
For areas with significant bone pain or high fracture risk, minimally invasive techniques such as bone cement injection (vertebroplasty) can alleviate pain and improve function.
5. Radiotherapy for local lesion control
For sites with severe bone destruction, such as spinal compression, localized precise radiotherapy can rapidly relieve symptoms and preserve neurological function.
Multiple myeloma affects patients through skeletal, renal, immune, and hematological complications. Treatment requires a combination of stem cell transplantation, immune cell reconstruction, targeted therapies, and minimally invasive methods. Experts at United Life International Medical Center emphasize that early standardized treatment and multi-modal strategies are key to delaying progression and improving quality of life.
